Personalized Medicine to Thrive the Entire Cancer Therapeutics Market in Future

Release Date: 28-Nov-2020

At global level, personalized medicine for the treatment of cancer patients is leading to the development of novel chapter for the researchers and the patients. Researchers across the globe are now aiming at targeting HER2 pathway so that breast cancer would be treated without developing any side effects in the patients that are adverse.


In the breast cancer therapeutics industry, the regulatory body i.e. the US FDA has already approved 2 novel drugs called as fam-trastuzumab deruxtecan-nxki (Enhertu) and tucatinib (Tukysa) for the treatment of cancer patients. Another drug called as Margetuximab, which is a novel monoclonal antibody is on the urge of getting approved by the regulatory body as it is already in the phase 3 of the development. In less than a time period, several efforts have led to the inclination of HER2-targeted therapy into other HER2-positive cancer types.


All the ongoing clinical trials for novel HER2-targeted therapies with respect to the treatment of gastric, colorectal (CRC), and nonandndash;small cell lung cancers (NSCLCs) are delivering promising results. Also, on the other side, researchers are on the urge of exploring the importance of HER3 when partnered with HER2 in order to drive the resistance to HER2-targeted therapy. In the clinical practice, HER3 targeted monoclonal antibodies have also delivered clinical efficacy, therefore, clinical trials with respect to the combination of HER2 and HER3 are estimated to be holding promising results. According to the researchers working on the respective clinical study, HER2 targeted treatment developed by the researchers is one of the best prime examples of power precision medicine in the overall cancer therapeutics industry and now combination of the therapy with HER3 will lead to more substantial result and increased cancer market acceptance.

Need custom market research solution? We can help you with that too.